Can bumetanide be a miraculous medicine for autism spectrum disorder: Meta-analysis evidence from randomized controlled trials / Han ZHU ; Jia-Qi JING ; Si-Jia JIA ; Su-Hong YU ; Chang-Jiang YANG in Research in Autism Spectrum Disorders, 114 (June 2024)  

Public ISBD [article]  inResearch in Autism Spectrum Disorders > 114 (June 2024) . - p.102363 Titre : Can bumetanide be a miraculous medicine for autism spectrum disorder: Meta-analysis evidence from randomized controlled trials Type de document : Texte imprimé et/ou numérique Auteurs : Han ZHU, Auteur ; Jia-Qi JING, Auteur ; Si-Jia JIA, Auteur ; Su-Hong YU, Auteur ; Chang-Jiang YANG, Auteur Année de publication : 2024 Article en page(s) : p.102363 Langues : Anglais (eng) Mots-clés : Bumetanide  Autism spectrum disorder  Overall core symptoms  Meta-analysis  Randomized controlled trials Index. décimale : PER Périodiques Résumé : Background The efficacy of bumetanide on autism spectrum disorders (ASD) has been extensively studied, but the results remain inconclusive, necessitating a critical examination to determine its therapeutic role. Therefore, this study conducted a meta-analysis of bumetanide treatments for ASD to explore its efficacy and identify subpopulation that responded positively. Methods A systematic search was conducted on PubMed, EMBASE, MEDLINE, PsyclNFO, Web of Science, Clinical Trials.gov, and references in reviews from the earliest available date to September 2023. Randomized controlled trials (RCTs) were identified that evaluated the efficacy of bumetanide in improving overall core symptoms (OCS) of ASD. Therefore, nine studies with 1036 participants were included in the study. Results Bumetanide showed significant effects on OCS of ASD (WMD = ? 1.91, p = 0.006), particularly in sub-domains including relation to inanimate objects, adaption to environment changes, auditory response, near sensory responses, anxiety and hyperactivity. Moderating analysis indicated that a significant effect size of bumetanide on OCS of ASD was observed in specific subgroup, including 3-6 years old (WMD = ?1.08, p = 0.008), the tablet (WMD = ?2.80, p = 0.003), 3-month intervention (WMD = ?2.54, p = 0.003), and the single-center studies (WMD = ?2.80, p = 0.003). Conclusions Bumetanide has a large and significant impact on the OCS of ASD. Given the limited number and quality of included RCTs, future research should prioritize conducting large-scale trials focusing on sub-parameters or specific clinical features to comprehensively evaluate the efficacy of bumetanide in subpopulations of children with ASD. En ligne : https://doi.org/10.1016/j.rasd.2024.102363 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=529 [article] Can bumetanide be a miraculous medicine for autism spectrum disorder: Meta-analysis evidence from randomized controlled trials [Texte imprimé et/ou numérique] / Han ZHU, Auteur ; Jia-Qi JING, Auteur ; Si-Jia JIA, Auteur ; Su-Hong YU, Auteur ; Chang-Jiang YANG, Auteur . - 2024 . - p.102363. Langues : Anglais (eng) in Research in Autism Spectrum Disorders > 114 (June 2024) . - p.102363 Mots-clés : Bumetanide  Autism spectrum disorder  Overall core symptoms  Meta-analysis  Randomized controlled trials Index. décimale : PER Périodiques Résumé : Background The efficacy of bumetanide on autism spectrum disorders (ASD) has been extensively studied, but the results remain inconclusive, necessitating a critical examination to determine its therapeutic role. Therefore, this study conducted a meta-analysis of bumetanide treatments for ASD to explore its efficacy and identify subpopulation that responded positively. Methods A systematic search was conducted on PubMed, EMBASE, MEDLINE, PsyclNFO, Web of Science, Clinical Trials.gov, and references in reviews from the earliest available date to September 2023. Randomized controlled trials (RCTs) were identified that evaluated the efficacy of bumetanide in improving overall core symptoms (OCS) of ASD. Therefore, nine studies with 1036 participants were included in the study. Results Bumetanide showed significant effects on OCS of ASD (WMD = ? 1.91, p = 0.006), particularly in sub-domains including relation to inanimate objects, adaption to environment changes, auditory response, near sensory responses, anxiety and hyperactivity. Moderating analysis indicated that a significant effect size of bumetanide on OCS of ASD was observed in specific subgroup, including 3-6 years old (WMD = ?1.08, p = 0.008), the tablet (WMD = ?2.80, p = 0.003), 3-month intervention (WMD = ?2.54, p = 0.003), and the single-center studies (WMD = ?2.80, p = 0.003). Conclusions Bumetanide has a large and significant impact on the OCS of ASD. Given the limited number and quality of included RCTs, future research should prioritize conducting large-scale trials focusing on sub-parameters or specific clinical features to comprehensively evaluate the efficacy of bumetanide in subpopulations of children with ASD. En ligne : https://doi.org/10.1016/j.rasd.2024.102363 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=529

Oxytocin therapy for core symptoms in autism spectrum disorder: An updated meta-analysis of randomized controlled trials / Yue WANG in Research in Autism Spectrum Disorders, 64 (August 2019)  

Public ISBD [article]  inResearch in Autism Spectrum Disorders > 64 (August 2019) . - p.63-75 Titre : Oxytocin therapy for core symptoms in autism spectrum disorder: An updated meta-analysis of randomized controlled trials Type de document : Texte imprimé et/ou numérique Auteurs : Yue WANG, Auteur ; Meng-Jie WANG, Auteur ; Ying RONG, Auteur ; Hui-Zhong HE, Auteur ; Chang-Jiang YANG, Auteur Article en page(s) : p.63-75 Langues : Anglais (eng) Mots-clés : Oxytocin  Autism spectrum disorder  Social function  Repetitive behaviors  Meta-analysis  Randomized controlled trials Index. décimale : PER Périodiques Résumé : Background Evidence of oxytocin for treating core symptoms in autism spectrum disorder (ASD) across development remains mixed and establishing its role is critical for guiding therapy. Aim The current paper is aimed to include new studies and provide a stricter and updated meta-analysis to assess the oxytocin's effects on core symptoms in ASD. Method Computerized search was conducted in PubMed, EMBASE, Cochrane Library, PsycINFO, Web of Science Database and references in reviews from the earliest date available to September 2018. Randomized controlled trials (RCTs) were identified which evaluated the effectiveness of oxytocin on at least one of two domains in patients with ASD, namely social function and repetitive behaviors. Standardized mean difference (SMD) and 95% confidence intervals (CIs) were calculated, and heterogeneity was assessed using the I2 test. Results Sixteen studies comprising 520 individuals with ASD were included in this meta-analysis. Results suggested that oxytocin had a small and non-significant effect on social function [SMD?=?0.03, 95% CI (?0.19, 0.25), p?=?0.781] and repetitive behaviors [SMD?=?0.01, 95% CI (?0.26, 0.27), p?=?0.952] compared with placebo. Studies included had a low heterogeneity (I2?=?46.4%, p?=?0.025 in social function; I2?=?37.0%, p?=?0.123 in repetitive behaviors). Conclusions The current meta-analysis demonstrated that oxytocin had a small and non-significant effect on core symptoms in ASD population. With the limited number of included studies, more large-scale, rigorously and multi-site RCTs are needed to confirm the effectiveness of oxytocin as a treatment of ASD to acquire more convincing conclusions in the future. En ligne : https://doi.org/10.1016/j.rasd.2019.03.007 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=399 [article] Oxytocin therapy for core symptoms in autism spectrum disorder: An updated meta-analysis of randomized controlled trials [Texte imprimé et/ou numérique] / Yue WANG, Auteur ; Meng-Jie WANG, Auteur ; Ying RONG, Auteur ; Hui-Zhong HE, Auteur ; Chang-Jiang YANG, Auteur . - p.63-75. Langues : Anglais (eng) in Research in Autism Spectrum Disorders > 64 (August 2019) . - p.63-75 Mots-clés : Oxytocin  Autism spectrum disorder  Social function  Repetitive behaviors  Meta-analysis  Randomized controlled trials Index. décimale : PER Périodiques Résumé : Background Evidence of oxytocin for treating core symptoms in autism spectrum disorder (ASD) across development remains mixed and establishing its role is critical for guiding therapy. Aim The current paper is aimed to include new studies and provide a stricter and updated meta-analysis to assess the oxytocin's effects on core symptoms in ASD. Method Computerized search was conducted in PubMed, EMBASE, Cochrane Library, PsycINFO, Web of Science Database and references in reviews from the earliest date available to September 2018. Randomized controlled trials (RCTs) were identified which evaluated the effectiveness of oxytocin on at least one of two domains in patients with ASD, namely social function and repetitive behaviors. Standardized mean difference (SMD) and 95% confidence intervals (CIs) were calculated, and heterogeneity was assessed using the I2 test. Results Sixteen studies comprising 520 individuals with ASD were included in this meta-analysis. Results suggested that oxytocin had a small and non-significant effect on social function [SMD?=?0.03, 95% CI (?0.19, 0.25), p?=?0.781] and repetitive behaviors [SMD?=?0.01, 95% CI (?0.26, 0.27), p?=?0.952] compared with placebo. Studies included had a low heterogeneity (I2?=?46.4%, p?=?0.025 in social function; I2?=?37.0%, p?=?0.123 in repetitive behaviors). Conclusions The current meta-analysis demonstrated that oxytocin had a small and non-significant effect on core symptoms in ASD population. With the limited number of included studies, more large-scale, rigorously and multi-site RCTs are needed to confirm the effectiveness of oxytocin as a treatment of ASD to acquire more convincing conclusions in the future. En ligne : https://doi.org/10.1016/j.rasd.2019.03.007 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=399

Prevalence of attention-deficit/hyperactivity disorder in individuals with autism spectrum disorder: A meta-analysis / Ying RONG in Research in Autism Spectrum Disorders, 83 (May 2021)  

Public ISBD [article]  inResearch in Autism Spectrum Disorders > 83 (May 2021) . - 101759 Titre : Prevalence of attention-deficit/hyperactivity disorder in individuals with autism spectrum disorder: A meta-analysis Type de document : Texte imprimé et/ou numérique Auteurs : Ying RONG, Auteur ; Chang-Jiang YANG, Auteur ; Ye JIN, Auteur ; Yue WANG, Auteur Article en page(s) : 101759 Langues : Anglais (eng) Mots-clés : Autism spectrum disorder  Attention-deficit/hyperactivity disorder  Current prevalence  Lifetime prevalence  Meta-analysis Index. décimale : PER Périodiques Résumé : Background Comorbidity with attention-deficit/hyperactivity disorder (ADHD) is very common in autism spectrum disorder (ASD), worsening the developmental trajectory of ASD. The reported rates of ADHD in ASD vary widely. However, no meta-analysis has been conducted specifically to assess both the current and lifetime prevalence of ADHD in ASD. This study aims to fill in this gap. Method We searched the Web of Science, PubMed, PsycINFO, CINAHL, and Embase databases for eligible articles published between January 1, 2000, and September 5, 2020. The risk of bias tool was used to assess the studies’ quality. Overall pooled estimates of the current and lifetime prevalence of ADHD in ASD were obtained using random-effects models. Study heterogeneity was examined by Q and I2 statistics. Findings A total of 63 articles were eventually included, of which 56 studies reported the current prevalence, and 13 studies reported the lifetime prevalence. The results revealed that the pooled current and lifetime prevalence rates of ADHD among ASD were 38.5 % (95 % CI 34.0–43.2) and 40.2 % (95 % CI 34.9–45.7), respectively. Our study also confirmed that age, intellectual disability, recruitment settings, and diagnostic criteria significantly influenced the current prevalence of ADHD in ASD. Conclusion ASD has considerable high current or lifetime prevalence rates of co-occurring ADHD. The findings demonstrate that clinicians should consider the high prevalence of ADHD in ASD and especially stay alert to possible ADHD diagnoses in school-age children and adolescents with ASD. Medical institutions should improve the assessment and tracking system of ADHD comorbidity in ASD and maximize the diagnostic accuracy for better treatment. En ligne : https://doi.org/10.1016/j.rasd.2021.101759 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=446 [article] Prevalence of attention-deficit/hyperactivity disorder in individuals with autism spectrum disorder: A meta-analysis [Texte imprimé et/ou numérique] / Ying RONG, Auteur ; Chang-Jiang YANG, Auteur ; Ye JIN, Auteur ; Yue WANG, Auteur . - 101759. Langues : Anglais (eng) in Research in Autism Spectrum Disorders > 83 (May 2021) . - 101759 Mots-clés : Autism spectrum disorder  Attention-deficit/hyperactivity disorder  Current prevalence  Lifetime prevalence  Meta-analysis Index. décimale : PER Périodiques Résumé : Background Comorbidity with attention-deficit/hyperactivity disorder (ADHD) is very common in autism spectrum disorder (ASD), worsening the developmental trajectory of ASD. The reported rates of ADHD in ASD vary widely. However, no meta-analysis has been conducted specifically to assess both the current and lifetime prevalence of ADHD in ASD. This study aims to fill in this gap. Method We searched the Web of Science, PubMed, PsycINFO, CINAHL, and Embase databases for eligible articles published between January 1, 2000, and September 5, 2020. The risk of bias tool was used to assess the studies’ quality. Overall pooled estimates of the current and lifetime prevalence of ADHD in ASD were obtained using random-effects models. Study heterogeneity was examined by Q and I2 statistics. Findings A total of 63 articles were eventually included, of which 56 studies reported the current prevalence, and 13 studies reported the lifetime prevalence. The results revealed that the pooled current and lifetime prevalence rates of ADHD among ASD were 38.5 % (95 % CI 34.0–43.2) and 40.2 % (95 % CI 34.9–45.7), respectively. Our study also confirmed that age, intellectual disability, recruitment settings, and diagnostic criteria significantly influenced the current prevalence of ADHD in ASD. Conclusion ASD has considerable high current or lifetime prevalence rates of co-occurring ADHD. The findings demonstrate that clinicians should consider the high prevalence of ADHD in ASD and especially stay alert to possible ADHD diagnoses in school-age children and adolescents with ASD. Medical institutions should improve the assessment and tracking system of ADHD comorbidity in ASD and maximize the diagnostic accuracy for better treatment. En ligne : https://doi.org/10.1016/j.rasd.2021.101759 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=446

The cortisol, serotonin and oxytocin are associated with repetitive behavior in autism spectrum disorder / Chang-Jiang YANG in Research in Autism Spectrum Disorders, 18 (October 2015)  

Public ISBD [article]  inResearch in Autism Spectrum Disorders > 18 (October 2015) . - p.12-20 Titre : The cortisol, serotonin and oxytocin are associated with repetitive behavior in autism spectrum disorder Type de document : Texte imprimé et/ou numérique Auteurs : Chang-Jiang YANG, Auteur ; He-Ping TAN, Auteur ; Fu-Yi YANG, Auteur ; He-Ping WANG, Auteur ; Chun-Ling LIU, Auteur ; Hui-Zhong HE, Auteur ; Biao SANG, Auteur ; Xiao-Mei ZHU, Auteur ; Yi-Jie DU, Auteur Article en page(s) : p.12-20 Langues : Anglais (eng) Mots-clés : Autism spectrum disorders  Repetitive behaviors  Cortisol  Serotonin  Oxytocin Index. décimale : PER Périodiques Résumé : Abstract Repetitive behaviors (RBs) are a core feature of autism spectrum disorders (ASD). They constitute a major barrier to learning and social adaptation. Research on potential causes of RBs is still at an early stage. However, promising new ideas and evidence are emerging from neurobiology. Instead of testing single neurotransmitter or hormone, the present study examined the associations of cortisol, serotonin, and oxytocin on subscales of repetitive behavior scales-revised (RBS-R). The results demonstrated that the individuals with ASD showed higher levels of cortisol areas under curve (cortisol AUC), higher levels of serotonin, and lower level of oxytocin compared with the typically developing (TD) individuals. For individuals with ASD, the levels of cortisol AUC, serotonin and oxytocin were all significantly associated with total scores measured by RBS-R. In addition, the cortisol AUC was positively associated with the stereotyped and restricted behavior subscales scores. The level of serotonin was positively associated with the stereotyped and self-injurious behavior subscales scores. The level of oxytocin was negatively associated with compulsive, sameness and restricted behavior subscales scores. Therefore, cortisol, serotonin and oxytocin may all be involved in the occurrence of RBs in ASD. The occurrence of RBs in ASD may due to a variety of pathological factors, not just one factor. En ligne : http://dx.doi.org/10.1016/j.rasd.2015.07.002 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=268 [article] The cortisol, serotonin and oxytocin are associated with repetitive behavior in autism spectrum disorder [Texte imprimé et/ou numérique] / Chang-Jiang YANG, Auteur ; He-Ping TAN, Auteur ; Fu-Yi YANG, Auteur ; He-Ping WANG, Auteur ; Chun-Ling LIU, Auteur ; Hui-Zhong HE, Auteur ; Biao SANG, Auteur ; Xiao-Mei ZHU, Auteur ; Yi-Jie DU, Auteur . - p.12-20. Langues : Anglais (eng) in Research in Autism Spectrum Disorders > 18 (October 2015) . - p.12-20 Mots-clés : Autism spectrum disorders  Repetitive behaviors  Cortisol  Serotonin  Oxytocin Index. décimale : PER Périodiques Résumé : Abstract Repetitive behaviors (RBs) are a core feature of autism spectrum disorders (ASD). They constitute a major barrier to learning and social adaptation. Research on potential causes of RBs is still at an early stage. However, promising new ideas and evidence are emerging from neurobiology. Instead of testing single neurotransmitter or hormone, the present study examined the associations of cortisol, serotonin, and oxytocin on subscales of repetitive behavior scales-revised (RBS-R). The results demonstrated that the individuals with ASD showed higher levels of cortisol areas under curve (cortisol AUC), higher levels of serotonin, and lower level of oxytocin compared with the typically developing (TD) individuals. For individuals with ASD, the levels of cortisol AUC, serotonin and oxytocin were all significantly associated with total scores measured by RBS-R. In addition, the cortisol AUC was positively associated with the stereotyped and restricted behavior subscales scores. The level of serotonin was positively associated with the stereotyped and self-injurious behavior subscales scores. The level of oxytocin was negatively associated with compulsive, sameness and restricted behavior subscales scores. Therefore, cortisol, serotonin and oxytocin may all be involved in the occurrence of RBs in ASD. The occurrence of RBs in ASD may due to a variety of pathological factors, not just one factor. En ligne : http://dx.doi.org/10.1016/j.rasd.2015.07.002 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=268

The roles of cortisol and pro-inflammatory cytokines in assisting the diagnosis of autism spectrum disorder / Chang-Jiang YANG in Research in Autism Spectrum Disorders, 9 (January 2015)  

Public ISBD [article]  inResearch in Autism Spectrum Disorders > 9 (January 2015) . - p.174-181 Titre : The roles of cortisol and pro-inflammatory cytokines in assisting the diagnosis of autism spectrum disorder Type de document : Texte imprimé et/ou numérique Auteurs : Chang-Jiang YANG, Auteur ; He-Ping TAN, Auteur ; Fu-Yi YANG, Auteur ; Chun-Ling LIU, Auteur ; Biao SANG, Auteur ; Xiao-Mei ZHU, Auteur ; Yi-Jie DU, Auteur Année de publication : 2015 Article en page(s) : p.174-181 Langues : Anglais (eng) Mots-clés : Autism spectrum disorders  Stress  Cortisol  IL-6  TNF-? Index. décimale : PER Périodiques Résumé : Abstract Autism spectrum disorders (ASD) is a severe neurodevelopmental disorder characterized by impairments in social interaction and repetitive behaviors. Diagnosis of ASD is currently phenotype based with no reliable laboratory test available to assist clinicians. The desire for clinically useful and reliable biomarkers is strong. Researches have shown that individuals with autism often exhibit dysfunction of hypothalamic–pituitary–adrenal (HPA) axis and cytokines. The purpose of this study was to evaluate diurnal variation of cortisol (cortisol VAR), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-?) as potential biomarkers for ASD. The present results demonstrated that in comparison to the healthy controls, the individuals with autism showed a lower level of cortisol VAR, higher level of IL-6 and TNF-?. The levels of cortisol VAR, IL-6 and TNF-? have significantly correlations with the severity of ASD measured by CARS scores. The results of ROC analysis indicated the cortisol VAR, IL-6 and TNF-? were potential biomarkers in diagnosis of ASD. The combination of three factors performed the best sensitivity and specificity for diagnosis of ASD. Therefore, the present study may reveal a simple clinical approach with great potential for assisting the diagnosis of ASD. En ligne : http://dx.doi.org/10.1016/j.rasd.2014.10.012 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=243 [article] The roles of cortisol and pro-inflammatory cytokines in assisting the diagnosis of autism spectrum disorder [Texte imprimé et/ou numérique] / Chang-Jiang YANG, Auteur ; He-Ping TAN, Auteur ; Fu-Yi YANG, Auteur ; Chun-Ling LIU, Auteur ; Biao SANG, Auteur ; Xiao-Mei ZHU, Auteur ; Yi-Jie DU, Auteur . - 2015 . - p.174-181. Langues : Anglais (eng) in Research in Autism Spectrum Disorders > 9 (January 2015) . - p.174-181 Mots-clés : Autism spectrum disorders  Stress  Cortisol  IL-6  TNF-? Index. décimale : PER Périodiques Résumé : Abstract Autism spectrum disorders (ASD) is a severe neurodevelopmental disorder characterized by impairments in social interaction and repetitive behaviors. Diagnosis of ASD is currently phenotype based with no reliable laboratory test available to assist clinicians. The desire for clinically useful and reliable biomarkers is strong. Researches have shown that individuals with autism often exhibit dysfunction of hypothalamic–pituitary–adrenal (HPA) axis and cytokines. The purpose of this study was to evaluate diurnal variation of cortisol (cortisol VAR), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-?) as potential biomarkers for ASD. The present results demonstrated that in comparison to the healthy controls, the individuals with autism showed a lower level of cortisol VAR, higher level of IL-6 and TNF-?. The levels of cortisol VAR, IL-6 and TNF-? have significantly correlations with the severity of ASD measured by CARS scores. The results of ROC analysis indicated the cortisol VAR, IL-6 and TNF-? were potential biomarkers in diagnosis of ASD. The combination of three factors performed the best sensitivity and specificity for diagnosis of ASD. Therefore, the present study may reveal a simple clinical approach with great potential for assisting the diagnosis of ASD. En ligne : http://dx.doi.org/10.1016/j.rasd.2014.10.012 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=243

---

1 (1 - 5 / 5)